MedTech Nuclera has secured a $12 million (£9m) financing extension, taking its Series C total to $87m (£65m).

The round was led by Elevage Medical Technologies and Jonathan Milner, alongside existing investors including the British Business Bank and GK Goh.

The funding will help Nuclera add new antibody testing features to its eProtein Discovery system, so researchers can produce and check antibodies in-house faster.

This upgrade will support the growing use of AI in drug development by helping teams generate the reliable data needed to train and improve new biologics models.

The Cambridge-headquartered firm, which also has offices in Boston, US, is developing a benchtop system that helps researchers rapidly produce and screen functional proteins for drug discovery.